Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

By Lourdes Riquelme

Using immunotherapy to treat cancer is one of the hottest trends in healthcare research right now. The latest collaboration in the field has been announced by Eli Lilly and the German Biotech BioNTech. They will identify and validate novel tumor targets and their corresponding T cell receptors (TCRs) in one Lire la suite

Source:: Labiotech

Les commentaires sont clos.